Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1809, Issue 3, 2011, Pages 157-165

  Renga, Barbara ^a   Migliorati, Marco ^a   Mencarelli, Andrea ^a   Cipriani, Sabrina ^a   D'Amore, Claudio ^a   Distrutti, Eleonora ^b   Fiorucci, Stefano ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Cholestasis; Constitutive androstane receptor; Farnesoid X receptor; Multidrug resistance associated protein 4; Overlapping binding site

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; CHENODEOXYCHOLIC ACID; CHOLIC ACID; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; LUCIFERASE; MULTIDRUG RESISTANCE PROTEIN 4;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL STRAIN HEPG2; CHOLESTASIS; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BASE SEQUENCE; BILE ACIDS AND SALTS; BINDING SITES; CELLS, CULTURED; DOWN-REGULATION; GENE DELETION; HEP G2 CELLS; HEPATOCYTES; HUMANS; KINETICS; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTAGENESIS; NUCLEAR RECEPTOR CO-REPRESSOR 1; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 79952487090     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2011.01.008     Document Type: Article

References (33)

1. Borst P., Oude Elferink R.P.J. Mammalian ABC transporters in health and disease. Ann. Rev. Biochem. 2002, 71:537-592.
2. Trauner M., Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 2003, 83:633-671.
3. Wielinga P.R., van der Heijden I., Reid G., Beijnen J.H., Wijnholds J., Borst P. Characterization of the MRP4- and MRP3-mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem. 2003, 278:17664-17671.
4. Belinsky M.G., Guo P., Lee K., Zhou F., Kotova E., Grinberg A., Westphal H., Shchaveleva I., Klein-Szanto A., Gallo J.M., Kruh G.D. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue induced damage. Cancer Res. 2007, 67:262-268.
5. van Aubel R.A., Smeets P.H., Peters J.G., Bindels R.J., Russel F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 2002, 13:595-603.
6. Zelcer N., Reid G., Wielinga P., Kuil A., van der Heijden I., Schuetz J.D., Borst P. Steroid and bile acid conjugates are substrates of human MRP4 (ABCC4). Biochem. J. 2003, 371:361-367.
7. Rius M., Nies A.T., Hummel-Eisenbeiss J., Jedlitschky G., Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003, 38:374-384.
8. Rius M., Hummel-Eisenbeiss J., Hofmann A.F., Keppler D. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290(4):G640-G649.
9. Denk G.U., Soroka C.J., Takeyama Y., Chen W.S., Schuetz J.D., Boyer J.L. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J. Hepatol. 2004, 40:585-591.
10. Kruh G.D., Belinsky M.G., Gallo J.M., Lee K. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene disrupted mice. Cancer Metastasis 2007, 26:5-14.
11. Moffit J.S., Aleksunes L.M., Maher J.M., Scheffer G.L., Klaassen C.D., Manautou J.E. Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. J. Pharmacol. Exp. Ther. 2006, 317(2):537-545.
12. Xu S., Weerachayaphorn J., Cai S.Y., Soroka C.J., Boyer J.L. Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299(1):G126-G135.
13. Assem M., Schuetz E.G., Leggas M., Sun D., Yasuda K., Reid G., Zelcer N., Adachi M., Strom S., Evans R.M., Moore D.D., Borst P., Schuetz J.D. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 2004, 279:22250-22257.
14. Kakizaki S., Takizawa D., Tojima H., Yamazaki Y., Mori M. Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease. Curr. Drug Targets 2009, 10(11):1156-1163.
15. Fiorucci S., Cipriani S., Baldelli F., Mencarelli A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res. 2010, 49(2):171-185.
16. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102:731-744.
17. Cui Y.J., Aleksunes L.M., Tanaka Y., Goedken M.J., Klaassen C.D. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol. Sci. 2009, 110(1):47-60.
18. Stedman C., Liddle C., Coulter S., Sonoda J., Alvarez J.G., Evans R.M., Downes M. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl Acad. Sci. 2006, 103:11323-11328. ED.
19. Iwano S., Ichikawa M., Takizawa S., Hashimoto H., Miyamoto Y. Identification of AhR-regulated genes involved in PAH-induced immunotoxicity using a highly-sensitive DNA chip, 3D-Gene Human Immunity and Metabolic Syndrome 9k. Toxicol. In Vitro 2010, 24(1):85-91.
20. Frank C., Gonzalez M.M., Oinonen C., Dunlop T.W., Carlberg C. Characterization of DNA complexes formed by the nuclear receptor constitutive androstane receptor. J. Biol. Chem. 2003, 278(44):43299-43310.
21. Claudel T., Sturm E., Duez H., Torra I.P., Sirvent A., Kosykh V., Fruchart J.C., Dallongeville J., Hum D.W., Kuipers F., Staels B. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 2002, 109(7):961-971.
22. Edwards P.A., Kast H.R., Anisfeld A.M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 2002, 43:2-12.
23. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., Tontonoz P., Kliewer S., Willson T.M., Edwards P.A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002, 277(4):2908-2915.
24. Vavassori P., Mencarelli A., Renga B., Distrutti E., Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 2009, 183(10):6251-6261.
25. Mennone A., Soroka C.J., Cai S.Y., Harry K., Adachi M., Hagey L., Schuetz J.D., Boyer J.L. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006, 43:1013-1021.
26. Beilke L.D., Aleksunes L.M., Olson E.R., Besselsen D.G., Klaassen C.D., Dvorak K., Cherrington N.J. Decreased apoptosis during CAR-mediated hepatoprotection against lithocholic acid-induced liver injury in mice. Toxicol. Lett. 2009 Jul 10, 188(1):38-44.
27. Beilke L.D., Aleksunes L.M., Holland R.D., Besselsen D.G., Beger R.D., Klaassen C.D., Cherrington N.J. Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab. Dispos. 2009 May, 37(5):1035-1045.
28. Stedman C.A., Liddle C., Coulter S.A., Sonoda J., Alvarez J.G., Moore D.D., Evans R.M., Downes M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl Acad. Sci. 2005, 102:2063-2068.
29. Liu Y., Binz J., Numerick M.J., Dennis S., Luo G., Desai B., MacKenzie K.I., Mansfield T.A., Kliewer S.A., Goodwin B., Jones S.A. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 2003, 112:1678-1687.
30. Renga B., Mencarelli A., Migliorati M., Distrutti E., Fiorucci S. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World J. Gastroenterol. 2009, 15(17):2097-2108.
31. Wagner M., Fickert P., Zollner G., Fuchsbichler A., Silbert D., Tsybrovskyy O., Zatloukal K., Guo G.L., Schuetz J.D., Gonzalez F.J., Marschall H.U., Denk H., Trauner M. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003, 125:825-838.
32. Gurevich I., Flores A.M., Aneskievich B.J. Corepressors of agonist-bound nuclear receptors. Toxicol. Appl. Pharmacol. 2007, 223(3):288-298.
33. Lonard D.M., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators and human disease. Endocr. Rev. 2007, 28(5):575-587.